Metabolism Drugs Market 2027 Application, Consumption, Market Share, Growth Opportunities, Regions

Metabolism diseases are caused by the body’s inherent metabolism malfunctioning or failing to work properly. Metabolism disorders can also be genetically based, as they can be caused by birth abnormalities. The incidence and prevalence of metabolic illnesses caused by genetic abnormalities are modest. Metabolism is the process of breaking down carbs, proteins, and lipids in food to produce energy. In addition, metabolism includes the excretion of nitrogen through urine, as well as the breakdown or conversion of other compounds and molecules. This metabolism is carried out by enzymes and proteins that are specifically designed for the job. However, metabolism functions improperly when enzymes and proteins are either not produced by the body (inherited disorders), or the produced enzymes do not function the way they are mean to.

Get PDF Brochure Here

Proteins, lipids, glycogen, urea, calcium stones, and toxic substances, among other things, cause metabolic disorders. These molecules each have their own metabolic pathways and metabolic agents (enzymes and proteins) at work. When these agents are unable to complete their tasks, molecules accumulate in the blood and other tissues. Few examples of metabolic diseases include gaucher disease, hereditary tyrosinemia, hereditary orotic aciduria, and fabry disease. 

Rising prevalence of metabolic diseases is expected to support growth of the metabolism drugs market over the forecast period

Metabolic diseases are a broad category, and there are a variety of metabolic disorders caused by both clinically uncomplicated and difficult-to-treat hereditary problems. Obesity, for example, is the most frequent type of metabolic illness and is linked to metabolic syndrome (a cluster of clinical conditions such as high blood sugar and triglycerides). According to the World Health Organization (WHO), over 650 million people aged 18 years and above were obese in 2016.

Another ailment known as lysosomal storage disease is an uncommon disorder that affects a large number of people. Lysosomal storage disease affects 1 in 4000 to 1 in 13,000 live births, according to a study published in Molecular Genetics and Metabolism Reports in December 2017. Lysosomal storage disease (LSD) is a group of 60 genetic disorders that cause problems with the lysosomes. Furthermore, other uncommon disorders, such as Hunter syndrome (Mucopolysaccaridosis type II (MPS II)), are life-threatening diseases for which there is no curative treatment, forcing patients to rely on current medications. According to the National Institute of Health 2018 report, Frequency of MPS II is 1 in 100,000 to 1 in 160,000 in males. Increasing incidence of hunter syndrome is expected to boost the metabolism disease drugs market. For instance, in 2014, around 970 patients were enrolled in Hunter Outcome Survey (HOC), which increased to 1195 patients in 2017.

The global metabolism drugs market size was valued at US$ 5,765.3 million in 2017, and is expected to witness a robust CAGR of 6.3% over the forecast period (2018 – 2026).

Newer therapy launches are expected to boost growth of the metabolism drugs market over the forecast period

By supplying effective medicines, manufacturers aim to uncover potential revenue-generating prospects in every illness segment. Despite the fact that rare diseases are uncommon, patients rely on medications that are made available regardless of cost. Despite the fact that these treatments are difficult to develop and hence expensive, manufacturers continue to develop remedies for chronic and difficult-to-cure uncommon diseases. Approvals to innovative therapies such as enzyme replacement therapy are expected to influence manufacturers to develop novel therapies in the market. This in turn, is expected to support the metabolism drugs market growth over the forecast period. The U.S. Food and Drug Administration (FDA) approved multiple drugs for gaucher disease. For instance, in 2010, FDA approved Vpriv (velaglucerase alfa), an enzyme replacement therapy (ERT), for type 1 gaucher disease. In 2012, Elelyso (taliglucerase alfa) and in 2014, Cerdelga (eliglustat) was approved by FDA for type 1 gaucher disease.

Furthermore, the market for metabolism medications is likely to benefit from research and development of novel therapeutics for the treatment of rare metabolic illnesses such as pompe and others. For example, the United States Food and Drug Administration granted Amicus Therapeutics orphan drug status for ATB200/AT2221 in October 2017 for the treatment of Pompe illness. Moreover, novel gene and RNAi therapies are also under research for treatment of these diseases.

The market for metabolism medications is projected to be restrained by the high cost of treatment and the long duration of treatment. Lumizyme, for example, cost US$ 100,000 per year for children and US$ 300,000 per year for adult pompe disease treatments in 2016, according to a Harvard School research article..

Purchase this Report at Discount Of US $2000 Flat OFF – https://www.coherentmarketinsights.com/promo/buynow/1955

Metabolism Drugs Market – Competitive Landscape

Key players functioning in the global prosthetic liners market consists of Merck & Co., Inc., Novartis AG, Amicus Therapeutics, AstraZeneca Plc, Boehringer Ingelheim, Shire Plc, Sanofi Genzyme, BioMarin Pharmaceutical, Inc., Horizon Pharma Plc, and GlaxoSmithKline Plc.

Main points in Metabolism Drugs Market Report Table of Content

Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Global Metabolism Drugs Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: Metabolism Drugs Industry Impact

Chapter 2 Global Metabolism Drugs Competition by Types, Applications, and Top Regions and Countries
2.1 Global Metabolism Drugs (Volume and Value) by Type
2.3 Global Metabolism Drugs (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Global Metabolism Drugs Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Metabolism Drugs Market Analysis
Chapter 6 East Asia Metabolism Drugs Market Analysis
Chapter 7 Europe Metabolism Drugs Market Analysis
Chapter 8 South Asia Metabolism Drugs Market Analysis
Chapter 9 Southeast Asia Metabolism Drugs Market Analysis
Chapter 10 Middle East Metabolism Drugs Market Analysis
Chapter 11 Africa Metabolism Drugs Market Analysis
Chapter 12 Oceania Metabolism Drugs Market Analysis
Chapter 13 South America Metabolism Drugs Market Analysis
Chapter 14 Company Profiles and Key Figures in Metabolism Drugs Business
Chapter 15 Global Metabolism Drugs Market Forecast (2021-2027)
Chapter 16 Conclusions
Research Methodology

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com